Also, using a genetic model of BRAFV600E kinase inhibitor resistance employing the A375NRAS isogenic melanoma cell line, our data indicate that D2O sustains activity irrespective of BRAF mutational status (an observation suggesting therapeutic efficacy targeting kinase-resistant melanoma cells using D2O (Figure 1A,E)). Here, BRAF is linked to melanoma.